Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients.

Objective: Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development. However, this drug is still prescribed as an "add-on" medication to achieve a better blood pressure (BP) control. The aim of this study was to evaluate the safety and efficacy of doxazosin as an "add-on" medication in HF patients with uncontrolled hypertension.

Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis.

Background: Disease management programmes (DMP) have been advocated to improve long term outcomes of heart failure (HF) patients.

Aims: To summarise the evidence supporting DMP effectiveness in improving HF clinical outcomes.

Methods: Eligible studies were located through a systematic literature search.

Effect of long-term therapy with ramipril in high-risk women.

Objectives: We evaluated the effects of long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor ramipril on major cardiovascular (CV) outcomes in high-risk women.

Background: The effect of long-term ACE inhibitor therapy in high-risk women without heart failure and with preserved left ventricular (LV) systolic function has not been previously reported.

Methods: The Heart Outcomes Prevention Evaluation (HOPE) trial is a large, randomized clinical trial that evaluated ramipril and vitamin E in high-risk patients.